Mastrandrea Lucy D, Quattrin Teresa
Division of Endocrinology-Diabetes, Department of Pediatrics, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, The Women's and Children's Hospital, 219 Bryant Street, Buffalo, New York 14222, USA.
Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1061-75. doi: 10.1016/j.addr.2006.07.019. Epub 2006 Aug 17.
Diabetes affects over 18.2 million individuals in the United States alone. Current therapy to treat type 1 diabetes relies on subcutaneous insulin administration either by injection or continuous infusion. In addition, patients with type 2 diabetes who fail lifestyle intervention and oral therapy require subcutaneous insulin. Optimal injection protocols to achieve tight metabolic control often prove burdensome to patients. Thus, development of pulmonary insulin delivery to supplement and/or replace subcutaneous insulin injections may be an effective alternative, allowing patients to achieve intensive diabetes management. This review will discuss the devices in development for the delivery of inhaled insulin. In addition, the efficacy of inhaled insulin in both type 1 and type 2 diabetic populations will be discussed. Finally, the available safety data with respect to the unique pulmonary effects of inhaled insulin will be covered.
仅在美国，糖尿病就影响着超过1820万人。目前治疗1型糖尿病的疗法依赖于通过注射或持续输注进行皮下胰岛素给药。此外，生活方式干预和口服治疗无效的2型糖尿病患者也需要皮下胰岛素。实现严格代谢控制的最佳注射方案往往对患者来说负担过重。因此，开发肺部胰岛素给药以补充和/或替代皮下胰岛素注射可能是一种有效的替代方法，使患者能够实现强化糖尿病管理。本综述将讨论正在开发的吸入胰岛素给药装置。此外，还将讨论吸入胰岛素在1型和2型糖尿病患者群体中的疗效。最后，将涵盖关于吸入胰岛素独特肺部效应的现有安全数据。
